Literature DB >> 7853373

Trinucleotide repeat length and progression of illness in Huntington's disease.

K Kieburtz1, M MacDonald, C Shih, A Feigin, K Steinberg, K Bordwell, C Zimmerman, J Srinidhi, J Sotack, J Gusella.   

Abstract

The genetic defect causing Huntington's disease (HD) has been identified as an unstable expansion of a trinucleotide (CAG) repeat sequence within the coding region of the IT15 gene on chromosome 4. In 50 patients with manifest HD who were evaluated prospectively and uniformly, we examined the relationship between the extent of the DNA expansion and the rate of illness progression. Although the length of CAG repeats showed a strong inverse correlation with the age at onset of HD, there was no such relationship between the number of CAG repeats and the rate of clinical decline. These findings suggest that the CAG repeat length may influence or trigger the onset of HD, but other genetic, neurobiological, or environmental factors contribute to the progression of illness and the underlying pace of neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853373      PMCID: PMC1016662          DOI: 10.1136/jmg.31.11.872

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

1.  Duration of illness in Huntington's disease is not related to age at onset.

Authors:  R A Roos; J Hermans; M Vegter-van der Vlis; G J van Ommen; G W Bruyn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

2.  Molecular analysis and clinical correlations of the Huntington's disease mutation.

Authors:  J C MacMillan; R G Snell; A Tyler; G D Houlihan; I Fenton; J P Cheadle; L P Lazarou; D J Shaw; P S Harper
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

3.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.

Authors:  S E Andrew; Y P Goldberg; B Kremer; H Telenius; J Theilmann; S Adam; E Starr; F Squitieri; B Lin; M A Kalchman
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

4.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.

Authors:  R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

5.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.

Authors:  J P Warner; L H Barron; D J Brock
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

7.  Huntington's disease in Venezuela: neurologic features and functional decline.

Authors:  A B Young; I Shoulson; J B Penney; S Starosta-Rubinstein; F Gomez; H Travers; M A Ramos-Arroyo; S R Snodgrass; E Bonilla; H Moreno
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

8.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15.

Authors:  O C Stine; N Pleasant; M L Franz; M H Abbott; S E Folstein; C A Ross
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

9.  Huntington's disease in Grampian region: correlation of the CAG repeat number and the age of onset of the disease.

Authors:  S A Simpson; M J Davidson; L H Barron
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

10.  A controlled clinical trial of baclofen as protective therapy in early Huntington's disease.

Authors:  I Shoulson; C Odoroff; D Oakes; J Behr; D Goldblatt; E Caine; J Kennedy; C Miller; K Bamford; A Rubin
Journal:  Ann Neurol       Date:  1989-03       Impact factor: 10.422

View more
  31 in total

Review 1.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

2.  Neurological proteins are not enriched for repetitive sequences.

Authors:  Melanie A Huntley; G Brian Golding
Journal:  Genetics       Date:  2004-03       Impact factor: 4.562

Review 3.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 4.  Huntington disease--another chapter rewritten.

Authors:  M A Nance
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 5.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

6.  Death of neuronal clusters contributes to variance of age at onset in Huntington's disease.

Authors:  Branka Cajavec; Hanspeter Herzel; Samuel Bernard
Journal:  Neurogenetics       Date:  2006-01-14       Impact factor: 2.660

7.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

Review 8.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

9.  Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

Authors:  Joel D Federspiel; Todd M Greco; Krystal K Lum; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2019-04-30       Impact factor: 5.911

Review 10.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.